Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial

J. Gordon, U. Udeh, K. Doobay, C. Magro, H. Wildman, M. Davids, J. N. Mersten, W. T. Huang, S. Lyman, M. K. Crow, R. F. Spiera

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Fingerprint Dive into the research topics of 'Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial'. Together they form a unique fingerprint.

Medicine & Life Sciences